ME Therapeutics Holdings, Inc. · NEO:METX
ME Therapeutics Holdings, Inc. financial statements
ME Therapeutics Holdings, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.
Financials
Annual, in CAD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Research and development | 412.1K | 312.0K | 27.1K | 54.7K |
| Selling, general and administrative | 780.1K | 1.06M | 950.2K | 97.3K |
| Operating income | -1.22M | -1.37M | -6.55M | -162.8K |
| Depreciation and amortization | 83.3K | 40 | 50 | 60 |
| EBITDA | -1.13M | -1.37M | -6.55M | -162.7K |
| Interest expense | 12.7K | 0 | 7.46K | 10.8K |
| Income before tax | -1.19M | -1.29M | -6.52M | -145.8K |
| Net income | -1.19M | -1.29M | -6.52M | -145.8K |
| Earnings per share, basic | -0.04 | -0.05 | -0.28 | -0.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 1.35M | 1.50M | 647.1K | 77.4K |
| Short-term investments | 57.5K | 0 | ||
| Current assets | 1.50M | 1.54M | 671.7K | 102.2K |
| Property, plant and equipment | 160 | 200 | 250 | |
| Total assets | 1.76M | 1.54M | 671.9K | 102.5K |
| Accounts payable | 155.2K | 46.1K | 106.7K | 34.2K |
| Current liabilities | 245.4K | 62.9K | 148.5K | 173.9K |
| Long-term debt | 0 | 60.0K | ||
| Total liabilities | 256.3K | 62.9K | 148.5K | 233.9K |
| Shareholders' equity | 1.50M | 1.48M | 523.4K | -131.5K |
| Shares outstanding | 29.6M | 25.2M | 23.6M | 23.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -862.3K | -657.9K | -303.2K | -135.7K |
| Capital spending | -216.2K | 0 | 0 | 0 |
| Free cash flow | -1.08M | -657.9K | -303.2K | -135.7K |
| Cash from investing | 0 | 757.4K | ||
| Cash from financing | 995.5K | 1.51M | 115.5K | 140.0K |
| Share buybacks | 1.55M | 0 | ||
| Change in cash | -151.3K | 849.6K | 569.8K | 4.32K |